EU regulator backs GSK's bone marrow cancer therapy

[November 13, 2023] 
(Reuters) - British drugmaker GSK on Monday said the human medicines committee of the European Medicines Agency had recommended approving its oral therapy to treat anaemia in patients with a type of bone marrow cancer called myelofibrosis.

A decision for the marketing authorization of the therapy, momelotinib, is expected by early 2024, GSK said in a statement.

(Reporting by Eva Mathews in Bengaluru; Editing by Sonia Cheema)

GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.